Suchergebnisse - "Aryanian, Zeinab"

PubPharm (10)

1

Rituximab as a maintenance treatment in patients with pemphigus vulgaris : When is the right time for discontinuation?

enthalten in: Journal of cosmetic dermatology | 2024

von Aryanian, Z. | Balighi, K. | Emadi, S. | +1

2

A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses : Special focus on indication and combination therapy

enthalten in: Experimental dermatology | 2023

von Kianfar, N. | Dasdar, S. | Daneshpazhooh, M. | +2

3

Rituximab Treatment and Improvement of Health-Related Quality of Life in Patients With Pemphigus

enthalten in: Cutis | 2023

von Aryanian, Z. | Balighi, K. | Nassimi, M. | +4

4

Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients : New evidence for the safety of rituximab

enthalten in: Dermatologic therapy | 2022

von Aryanian, Z. | Tahooneban, A. | Balighi, K. | +6

5

Retrospective study of gingival involvement in pemphigus : A difficult to treat phenomenon

enthalten in: Dermatologic therapy | 2022

von Balighi, K. | Shams-Davatchi, C. | Ghobadi, S. | +8

6

Multiple cycles of rituximab therapy for pemphigus : A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?

enthalten in: Dermatologic therapy | 2022

von Balighi, K. | Hatami, P. | Sheikh Aboli, M. | +4

7

Evaluating the risk-to-benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab : A retrospective study with 494 patients

enthalten in: Dermatologic therapy | 2022

von Faraji, H. | Daneshpazhooh, M. | Ehsani, A. | +6

8

COVID vaccination in patients under treatment with rituximab : A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus

enthalten in: Dermatologic therapy | 2022

von Hatami, P. | Balighi, K. | Nicknam Asl, H. | +1

9

A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus : special focus on COVID-19 pandemic concerns

enthalten in: Immunopharmacology and immunotoxicology | 2021

von Tavakolpour, S. | Aryanian, Z. | Seirafianpour, F. | +6

10

Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris : A retrospective study

enthalten in: International immunopharmacology | 2021

von Aryanian, Z. | Balighi, K. | Daneshpazhooh, M. | +5

1
[1]